Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives

References

• World Health Organization. Influenza. WHO recommendations on the composition of influenza virus vaccines. 2018. [accessed 2018 Dec]. http://www.who.int/influenza/vaccines/virus/recommendations/en/
   Google Scholar
• Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, Marcos C, Matthews S, Meijer C, Poscia A, et al. A report on the status of vaccination in Europe. Vaccine. 2018;36(33):4979–92. doi:10.1016/j.vaccine.2018.06.044.
   PubMed Web of Science ®Google Scholar
• Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813. doi:10.1186/1471-2458-14-813.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. (EMA/PRAC/222346/2014). 2014. [accessed 2018 Dec]. https://www.ema.europa.eu/documents/scientific-guideline/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf
   Google Scholar
• European Medicines Agency. Guideline on influenza vaccines. Non-clinical and clinical model. (EMA/CHMP/VWP/457259/2014). 2016. [accessed 2018 Dec]. https://www.ema.europa.eu/documents/scientific-guideline/influenza-vaccines-non-clinical-clinical-module_en.pdf
   Google Scholar
• European Medicines Agency. Note for guidance on harmonisation of requirements for influenza vaccines. 1997. [Accessed 2018 Dec]. https://www.ema.europa.eu/documents/scientific-guideline/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf
   Google Scholar
• European Medicines Agency. Explanatory note on the withdrawal of the note for guidance on harmonization of requirements for influenza vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines. (EMA/CHMP/VWP/40560/2014). 2014. [accessed 2018 Dec]. https://www.ema.europa.eu/documents/scientific-guideline/explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines-core-summary_en-0.pdf
   Google Scholar
• Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1(1):e000016. doi:10.1136/bmjopen-2010-000016.
   PubMed Web of Science ®Google Scholar
• Blyth CC, Cheng AC, Finucane C, Jacoby P, Effler PV, Smith DW, Kelly H, Macartney KK, Richmond PC. The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia. Vaccine. 2015;33(51):7239–44. doi:10.1016/j.vaccine.2015.10.122.
   PubMed Web of Science ®Google Scholar
• Levi M, Sinisgalli E, Lorini C, Santomauro F, Chellini M, Bonanni P. The “Fluad Case” in Italy: could it have been dealt differently?. Hum Vaccin Immunother. 2017;13(2):379–84. doi:10.1080/21645515.2017.1264738.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations I: vaccines for prophylaxis against infectious diseases. (EMA/488220/2012). 2013. [accessed 2018 Dec]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/12/WC500157839.pdf
   Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VIII – post-authorisation safety studies. (rev 3; EMA/813938/2011 Rev 3*). 2017. [accessed 2018 Dec]. https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf
   Google Scholar
• Demeulemeester M, Lavis N, Balthazar Y, Lechien P, Heijmans S. Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine. Hum Vaccin Immunother. 2017;13(4):889–94. doi:10.1080/21645515.2016.1253644.
   PubMed Web of Science ®Google Scholar
• McNaughton R, Lynn E, Osborne V, Coughtrie A, Layton D, Shakir S. Safety of intranasal quadrivalent live attenuated influenza vaccine (QLAIV) in children and adolescents: a pilot prospective cohort study in England. Drug Saf. 2016;39:323–33. doi: 10.1007/s40264-015-0384-7
   PubMed Web of Science ®Google Scholar
• Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 microg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;22:18. doi:10.2807/1560-7917.ES.2017.22.18.30527.
   Google Scholar
• Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, Pascucci MG, Aquilani S, Spadea A, Tafuri S, et al.. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health. 2018;18(1):1401. doi:10.1186/s12889-018-6260-5.
   PubMedGoogle Scholar
• Chabanon AL, Bricout H, Ballandras C, Souverain A, Caroe TD, Butler KM. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 mug) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Hum Vaccin Immunother. 2018;14(2):378–85. doi:10.1080/21645515.2017.1405882.
   PubMed Web of Science ®Google Scholar
• Stuurman AL, Verstraeten T, De Schryver A. Rapid assessment of the reactogenicity of a 2016–2017 seasonal influenza vaccine: results from a feasibility study. Expert Rev Vaccines. 2017;16(2):187–91. doi:10.1080/14760584.2017.1264272.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Ferreira F, Damaso S, Byford S, Pathirannehelage S, Yeakey A, Yonova I, Schuind A, Dos Santos G. Enhanced passive surveillance of influenza vaccination in England, 2016–2017 – an observational study using an adverse events reporting card. Hum Vaccin Immunother. 2019. doi:10.1080/21645515.2019.1565258.
   PubMedGoogle Scholar
• Gandhi-Banga S, Chabanon A-L, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccin Immunother. 2019. doi:10.1080/21645515.2019.1581538.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Correa A, Dos Santos G, Meyer N, Haguinet F, Webb R, McGee C, Byford R, Yonova I, Pathirannehelage S, et al. Enhanced safety surveillance of influenza vaccines in general practice winter 2015/16: feasibility study and lessons learned. JMIR Public Health and Surveillance. 2019.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: pilot study in England. NCT03278067. 2018. [accessed 2019 Mar] https://clinicaltrials.gov/ct2/show/NCT03278067
   Google Scholar
• Alguacil-Ramos AM, Portero-Alonso A, Pastor-Villalba E, Muelas-Tirado J, Díez-Domingo J, Sanchis-Ferrer A, Lluch-Rodrigo JA. Rapid assessment of enhanced safety surveillance for influenza vaccine. Public Health. 2019;168:137–41. doi:10.1016/j.puhe.2018.12.013.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Dos Santos G, Correa A, Haguinet F, Yonova I, Lair F, Byford R, Ferreira F, Stuttard K, Chan T. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England. BMJ Open. 2017;7(5):e015469. doi:10.1136/bmjopen-2016-015469.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Dos Santos G, Byford R, Schuind A, Damaso S, Shende V, McGee C, Yonova I, Ferreira F. Enhanced safety surveillance of seasonal quadrivalent Influenza vaccines in English primary care: interim Analysis. Adv Ther. 2018. doi:10.1007/s12325-018-0747-4.
   PubMed Web of Science ®Google Scholar
• McGuire A, Drummond M, Keeping S. Childhood and adolescent influenza vaccination in Europe: a review of current policies and recommendations for the future. Expert Rev Vaccines. 2016;15(5):659–70. doi:10.1586/14760584.2016.1138861.
   PubMed Web of Science ®Google Scholar
• Moro PL, Li R, Haber P, Weintraub E, Cano M. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention. Expert Opin Drug Saf. 2016;15(9):1175–83. doi:10.1080/14740338.2016.1194823.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting Scheme (VAERS). 2018. [accessed: 2018 Aug]. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html.
   Google Scholar
• Canadian Immunization Research Network. Canadian National Vaccine Safety Network (CANVAS) - Influenza safety surveillance. 2018. [accessed: 2018 Aug]. http://cirnetwork.ca/research-study/influenza-vaccine-adverse-event-surveillance-in-health-care-workers-seniors-and-young-children/.
   Google Scholar
• Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, Purcell P, Isaacs D. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell Q Rep. 2003;27:307–23.
   PubMedGoogle Scholar
• Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Your guide to adverse reaction reporting. 2001. [accessed: 2018 aug]. http://www.medsafe.govt.nz/profs/PUarticles/ADRreport.htm
   Google Scholar
• ANVISA. Results 2017. 2017. [accessed: 2018 Sep]. http://portal.anvisa.gov.br/documents/281258/2742545/Folder+-+Results+2017/4aea5387-8a3e-4325-a6f6-3e109533ffb8.
   Google Scholar
• ANVISA. Nota Técnica nº102/2015/GGPBS/GGMON/SUMED/SUCOM/ANVISA. 2015. 2015.
   Google Scholar
• Cassidy C, MacDonald NE, Steenbeek A, Ortiz JR, Zuber PL, Top KA. A global survey of adverse event following immunization surveillance systems for pregnant women and their infants. Hum Vaccin Immunother. 2016;12(8):2010–16. doi:10.1080/21645515.2016.1175697.
   PubMed Web of Science ®Google Scholar
• Broder KR, Martin DB, Vellozzi C. In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010–11 influenza vaccine in young children, United States. Vaccine. 2012;30(11):2032–34. doi:10.1016/j.vaccine.2011.12.040.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Rouleau I, Gariepy MC, Bowie WR, Valiquette L, Vanderkooi OG, Kellner JD, Coleman BL, McNeil SA, McCarthy A, et al. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012. Euro Surveill. 2015;20(29):21189. doi:10.2807/1560-7917.ES2015.20.29.21189.
   PubMedGoogle Scholar
• Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294–98.
   PubMedGoogle Scholar
• Clothier HJ, Crawford N, Russell MA, Buttery JP. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia. Euro Surveill. 2017;22:20. doi:10.2807/1560-7917.ES.2017.22.20.30535.
   Google Scholar
• Government of Western Australia - Department of Health. Western Australian Vaccine Safety Surveillance (WAVSS). 2018. East Perth, Australia: Government of Western Australia; 2018.
   Google Scholar
• Mansoor O, Pillans PI. Vaccine adverse events reported in New Zealand 1990–5. N Z Med J. 1997;110:270–72.
   PubMed Web of Science ®Google Scholar
• Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P, Leeb A, Blyth CC, Gold MS, Snelling T, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10):e023263. doi:10.1136/bmjopen-2018-023263.
   PubMed Web of Science ®Google Scholar
• Regan AK, Blyth CC, Tracey L, Mak DB, Richmond PC, Effler PV. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation. Vaccine. 2015;33(31):3689–94. doi:10.1016/j.vaccine.2015.06.022.
   PubMed Web of Science ®Google Scholar
• Cashman P, Moberley S, Dalton C, Stephenson J, Elvidge E, Butler M, Durrheim DN. Vaxtracker: active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014;32(42):5503–08. doi:10.1016/j.vaccine.2014.07.061.
   PubMed Web of Science ®Google Scholar
• Wilson K, Atkinson KM, Westeinde J, Bell C, Marty K, Fergusson D, Deeks SL, Crowcroft N, Bettinger JA. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination. Hum Vaccin Immunother. 2016;12(7):1738–48. doi:10.1080/21645515.2016.1152434.
   PubMed Web of Science ®Google Scholar
• Botsis T, Nguyen MD, Woo EJ, Markatou M, Ball R. Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. J Am Med Inform Assoc. 2011;18(5):631–38. doi:10.1136/amiajnl-2010-000022.
   PubMed Web of Science ®Google Scholar
• Van Holle L, Zeinoun Z, Bauchau V, Verstraeten T. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. Pharmacoepidemiol Drug Saf. 2012;21(6):603–10. doi:10.1002/pds.3226.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Hoghton M, Rafi I. Flu vaccination by pharmacists leads to suboptimal medical records. BMJ. 2017;359:j5084. doi:10.1136/bmj.j5084.
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations II: biological medicinal products. 2016. [accessed 2018 Dec]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211728.pdf
   Google Scholar
• European Commission. Commission delegated regulation (EU) 2016/161. Brussels, Belgium: European Commission; 2016. [accessed: 2018 Sep]. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2016_161/reg_2016_161_en.pdf.
   Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96. doi:10.2165/00002018-200629050-00003.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. doi:10.2165/00002018-200932010-00002.
   PubMed Web of Science ®Google Scholar
• White RW, Harpaz R, Shah NH, DuMouchel W, Horvitz E. Toward enhanced pharmacovigilance using patient-generated data on the internet. Clin Pharmacol Ther. 2014;96(2):239–46. doi:10.1038/clpt.2014.77.
   PubMed Web of Science ®Google Scholar
• Perez-Vilar S, Weibel D, Sturkenboom M, Black S, Maure C, Castro JL, Bravo-Alcántara P, Dodd CN, Romio SA, de Ridder M, et al.. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine. 2018;36(3):347–54. doi:10.1016/j.vaccine.2017.05.012.
   PubMed Web of Science ®Google Scholar
• Maure CG, Dodoo AN, Bonhoeffer J, Zuber PLF. The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level. Bull World Health Organ. 2014;92(9):695–96. doi:10.2471/BLT.14.138875.
   PubMed Web of Science ®Google Scholar